Business context and reporting period
Haleon plc’s Form 20-F is an annual report for the fiscal year ended December 31, 2023, prepared under IFRS as issued by the IASB. It covers the global consumer healthcare business across Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, and Digestive Health and Other. The filing does not provide a clear standalone fourth-quarter income statement; figures below are full-year unless noted.
Financial performance and position
| Metric | 2023 | 2022 | Change or context |
|---|---|---|---|
| Revenue | £11.302bn | £10.858bn | +4.1% reported; +8.0% organic. Foreign exchange reduced reported growth by 3.8 percentage points. |
| Operating profit | £1.996bn | £1.825bn | +9.4%; reported operating margin rose to 17.7% from 16.8%. |
| Adjusted operating profit | £2.549bn | £2.472bn | +3.1% reported; +10.4% at constant currency and +10.8% organic. Adjusted margin was 22.6%, versus 22.8%. |
| Profit after tax attributable to shareholders | £1.049bn | £1.060bn | Diluted EPS was 11.3p, down from 11.5p; adjusted diluted EPS was 17.3p, down from 18.4p. |
| Net finance costs | £368m | £207m | Increase mainly reflects a full year of interest costs on debt issued in 2022. |
| Cash flow | £2.100bn operating cash inflow; £1.575bn free cash flow | £2.063bn; £1.579bn | Free cash flow was broadly flat. |
| Net debt / liquidity | £8.514bn net debt; £1.044bn cash | £9.868bn; £684m | Leverage improved to 3.0x adjusted EBITDA from 3.6x. Total liquidity was £2.914bn, including undrawn facilities. |
Reported gross margin declined to 59.7% from 60.6%; adjusted gross margin declined to 61.9% from 62.4%, with pricing and efficiency gains partly offsetting input-cost inflation. The statutory effective tax rate was 31.8%, including a £155m non-cash tax charge associated with intragroup transfers; the adjusted rate was 23.5%.
Material changes versus the prior comparable period
- Organic revenue growth slowed to 8.0% from 9.0%, while reported growth fell to 4.1% from 13.8%, partly reflecting adverse foreign exchange.
- Growth varied by category: Respiratory Health +13.7% organic, Oral Health +10.6%, Pain Relief +7.4%, Digestive Health and Other +6.5%, and VMS +0.9%. VMS was affected by normalization in immunity products after pandemic-related demand.
- Net debt fell by £1.354bn and leverage improved from 3.6x to 3.0x, supported by cash generation and debt repayment.
- Net finance costs increased £161m, contributing to lower adjusted EPS despite higher operating profit.
- The company recorded £169m of restructuring costs, mainly related to its productivity programme, compared with £41m in 2022.
Outlook, management commentary, risks and unusual items
- Management’s medium-term guidance is 4–6% annual organic revenue growth, organic operating profit growth ahead of organic revenue growth, and leverage around 2.5x net debt/adjusted EBITDA. For 2024, Haleon expects organic revenue growth of 4–6% and organic profit growth ahead of revenue growth.
- A three-year productivity programme is expected to deliver approximately £300m of annualised gross savings, largely in 2024 and 2025; around one-third of the benefit is expected in 2024. The programme involves structural changes and severance.
- The Board proposed a 4.2p final dividend, bringing the stated 2023 total dividend to 6.0p per ordinary share, subject to shareholder approval. Haleon announced a £500m share-buyback allocation for 2024 and intends to grow the dividend at least in line with adjusted earnings.
- Haleon completed the Lamisil disposal for £235m and agreed to sell ChapStick for approximately $430m, plus a passive minority interest in Suave Brands Company. ChapStick was classified as held for sale; an impairment of £170m was recorded. The filing also reports a £15m impairment of smaller brands.
- Key risks include competition and execution of innovation, inflation and input costs, supply-chain disruption, product safety and ingredient scrutiny, cyber-security, geopolitical and foreign-exchange exposures, retailer concentration, regulatory change, and climate and sustainability obligations. The company reported no significant cyber-security incident in 2023.
- Legal and contingent matters include product-liability and competition proceedings. Haleon is not a party to US or Canadian Zantac claims but has received and rejected indemnification requests from GSK and Pfizer; the ultimate exposure is not reliably estimable. The PPI litigation settlement for the vast majority of pending cases was recognized in 2022. Contingent liabilities were £29m; uncertain tax-position provisions were £148m.
- Haleon’s China TSK&F joint-venture agreement was due to expire in September 2024; discussions on an extension or alternative arrangements were ongoing. The company identified no material short-term climate-related impact on financial-statement estimates.
- The 2023 financial statements received an unqualified audit opinion, and the auditor concluded internal control over financial reporting was effective as of December 31, 2023. Preparation H’s £1.103bn carrying value remains sensitive to assumptions: a 0.5 percentage-point higher discount rate or lower terminal growth rate would imply estimated impairments of £115m or £75m, respectively.
Most important facts for investors to verify
- How much 2024 organic growth and operating-profit growth are delivered, and the contribution of price versus volume, given 2023 organic growth relied mainly on pricing.
- Whether the productivity programme achieves the stated savings on schedule and without impairing growth, brand investment, or execution.
- Debt repayment, refinancing of the $700m March 2024 and $1.75bn March 2025 maturities, and progress toward the 2.5x leverage target.
- Completion terms and cash proceeds for the ChapStick disposal, including the value and implications of the Suave minority interest.
- Developments in the China joint venture, Zantac indemnity requests, other litigation, and uncertain tax positions.
- Progress against medium-term guidance and sustainability commitments; adjusted measures are non-IFRS and should be assessed alongside reported IFRS results.